The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
Authors
Keywords
-
Journal
mBio
Volume 12, Issue 4, Pages -
Publisher
American Society for Microbiology
Online
2021-08-03
DOI
10.1128/mbio.00970-21
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
- (2021) Anna Z Mykytyn et al. eLife
- Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
- (2021) Markus Hoffmann et al. EBioMedicine
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
- (2020) Nanshan Chen et al. LANCET
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
- (2020) Markus Hoffmann et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Camostat mesilate therapy for COVID-19
- (2020) Yoshiharu Uno Internal and Emergency Medicine
- Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy
- (2020) Sukbin Jang et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection
- (2020) Gregory Brett Moreau et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment
- (2020) Jing Sun et al. CELL
- A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies
- (2020) Ahmed O. Hassan et al. CELL
- Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells
- (2020) Meehyun Ko et al. JOURNAL OF MEDICAL VIROLOGY
- The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner
- (2020) Mizuki Yamamoto et al. Viruses-Basel
- Publisher Correction: SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function
- (2020) Emma S. Winkler et al. NATURE IMMUNOLOGY
- Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease
- (2020) Joseph W. Golden et al. JCI Insight
- The clinically used serine protease inhibitor nafamostat reduces influenza virus replication and cytokine production in human airway epithelial cells and viral replication in mice
- (2020) Mutsuo Yamaya et al. JOURNAL OF MEDICAL VIROLOGY
- Principles and approaches for reproducible scoring of tissue stains in research
- (2018) David K. Meyerholz et al. LABORATORY INVESTIGATION
- Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay
- (2016) Mizuki Yamamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Protease inhibitors targeting coronavirus and filovirus entry
- (2015) Yanchen Zhou et al. ANTIVIRAL RESEARCH
- The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells
- (2015) Mutsuo Yamaya et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2
- (2013) Kazuya Shirato et al. JOURNAL OF VIROLOGY
- Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry
- (2012) M. Kawase et al. JOURNAL OF VIROLOGY
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
- (2012) Ali M. Zaki et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started